Clinical Trial Update: Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety and exploratory efficacy study of SF0166 for neovascular age-related macular degeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• SF0166

Snippet

Sponsor: OcuTerra Therapeutics, Inc. | Conditions: Age-Related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-06-07